Due to ethical and legal considerations, we are unable to share de-identified individual-level data; only aggregate data are included in the manuscript.

Introduction {#sec007}
============

Between 2014 and 2016, the US welcomed an annual average of 75,000 refugees, 9,900 Special Immigrant Visa holders (SIVHs), and 23,000 persons granted asylum (asylees) \[[@pmed.1003065.ref001]\]. Before US resettlement, these populations may have spent years without access to routine, preventive healthcare \[[@pmed.1003065.ref002]\]. To address healthcare gaps and ensure healthy resettlement in the US, the immigration process includes multiple health screening exams and interventions \[[@pmed.1003065.ref003]\].

Under section 325 of the Public Health Service Act (42 USC 252) and sections 212 and 232 of the Immigration and Nationality Act (8 USC 1182, 1222), refugees, SIVHs, and derivative asylees (persons applying outside of the US) are required to undergo a medical exam before admission to the US to detect the presence of inadmissible health conditions. These medical exams are conducted by physicians contracted by the US Department of State and are performed according to US Centers for Disease Control and Prevention (CDC) *Technical Instructions for the Medical Examination of Aliens* \[[@pmed.1003065.ref003]\]. In addition, US-bound refugees (but not other visa types) are eligible for overseas health interventions such as predeparture screening, the voluntary Vaccination Program for US-bound Refugees, and the presumptive parasite treatment program \[[@pmed.1003065.ref003]\]. Asylees granted their status after US arrival do not receive overseas screening or interventions \[[@pmed.1003065.ref004]\].

After US arrival or certification, refugees, SIVHs, asylees, Cuban/Haitian entrants (parolees), Amerasians (a visa status available to children born in Vietnam of US citizen fathers after January 1, 1962, and before January 1, 1976, and their eligible dependents), and certified victims of human trafficking are eligible for benefits, including a recommended medical screening examination that addresses health conditions diagnosed overseas, identifies additional health concerns, and connects the individuals with the US healthcare system \[[@pmed.1003065.ref003],[@pmed.1003065.ref005]\]. CDC provides *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees*, but state or local refugee health programs independently coordinate the examination, and these guidelines may be adapted for local use \[[@pmed.1003065.ref006],[@pmed.1003065.ref007]\]. The comprehensive examination includes a medical history and physical examination, screening for select communicable diseases, nutritional status assessment, blood lead screening for children \<17 years old, and immunization administration according to US schedules \[[@pmed.1003065.ref007]\].

Examinations and interventions provided during the initial resettlement period ensure that refugees and other eligible populations are healthily integrated into receiving communities and are ready to begin work and school. Further, the domestic examination is usually the first contact the individual has with the US healthcare system and possibly the first time he/she is screened for certain health conditions or receives preventive healthcare \[[@pmed.1003065.ref008],[@pmed.1003065.ref009]\].

Assessing the impact of the domestic examination on the recipient as well as on the receiving community has been challenging. Data from these examinations are not routinely collected at the national level, and state capacity to collect and analyze these data varies. In a review of the literature, we found that most analyses based on domestic medical examination data occur at the clinic, state, or local levels \[[@pmed.1003065.ref010]\] and may not represent all recipients of refugee health program services, given the heterogeneity of these populations. Where domestic examination data are pooled across states or sites, analyses are generally limited to a particular condition (e.g., hepatitis B, lead) or population (e.g., children) \[[@pmed.1003065.ref011]--[@pmed.1003065.ref014]\]. Finally, we identified few analyses that reported the proportion of persons screened by condition during the domestic medical examination \[[@pmed.1003065.ref010]--[@pmed.1003065.ref012]\], which, to our knowledge, prevents assessment of the impact of the domestic examination on screening coverage. Accordingly, we conducted, to our knowledge, a novel analysis to assess screening coverage during the domestic medical examination on screening coverage for various conditions by calculating and comparing screening proportions among refugees and other visa holders by select demographic characteristics.

Methods {#sec008}
=======

We conducted a retrospective, cross-sectional analysis of data derived from domestic medical examinations administered to refugees, SIVHs, asylees, parolees, and victims of trafficking between January 1, 2014, and December 31, 2016, in seven states (California, Colorado, Minnesota, New York, Kentucky, Illinois, and Texas); one county (Marion County, Indiana); and one academic medical center in Philadelphia, Pennsylvania. These sites provided their data as part of the CDC-funded CK12-1205 Strengthening Surveillance for Diseases among Newly Arrived Immigrants and Refugees nonresearch cooperative agreement administered by CDC. At least one representative of each site participated in the data collection and analysis of data. Although this is a convenience sample and not generalizable to all refugees in the US, the data set includes data from three states (California, Texas, and New York) with the highest volume of refugee, asylee, and SIVH arrivals between 2014 and 2016 and represents 28% of all refugee, asylee, and SIVH arrivals to the US during the same period. As part of a larger data collection effort, this analysis was not guided by a specific prospective analysis plan. However, the variables collected for analysis were outlined in a protocol used for ethical determination and shared with site partners contributing data. After data collection, we assessed the quality and availability of our data and identified appropriate analyses, including this descriptive analysis to assess screening coverage. This activity received a nonresearch determination from a CDC human subjects adviser and was exempt from further ethics review.

We suggested the variables and formats to compile the data to the nine participating site data partners. If partners could not provide those variables, they shared comparable raw data with explanations for missing variables or data. We then recoded the raw data for inclusion in the combined data set. Most data were collected from the state or local refugee health program databases, but some partners obtained data from other state or local programs (e.g., tuberculosis \[TB\] control or lead poisoning) because those data were not in the refugee program database. Some sites' restrictions on sharing personally identifying information prevented them from sharing birth and arrival dates; instead, they provided age at arrival and arrival year as proxy variables. Sites either provided nationality and country of last residence or shared a unique identifier we used to link to the US Department of State's Worldwide Refugee Admissions Processing System (78.1% of records linked) and CDC's Electronic Disease Notification system (74.0% linked) to obtain these two variables. Nationality or country of last residence were left blank or imputed from country of birth for records that did not match. Other than the unique identifier and birth date, we did not collect or store personally identifying information. Data were transmitted to CDC via secure file transfer and stored behind CDC's firewall and physical security measures; access to raw data was limited to a few CDC refugee health program staff.

Demographic variables were age (in years), sex, arrival year, visa status, nationality, and country of last residence (generally the country of asylum for refugees). For our outcome of interest, screening status, we created a bivariate variable of "screened," which included all persons a site reported to be screened, regardless of outcome, and "not screened," which included persons who were not screened; screening status was known for all persons. We examined results for conditions with screening recommended by CDC's *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees* ([Table 1](#pmed.1003065.t001){ref-type="table"}): TB (using interferon gamma release assays \[IGRAs\] or tuberculin skin tests \[TST\]; screening tests do not distinguish between latent TB infection \[LTBI\] and TB disease), hepatitis B (results from hepatitis B surface antigen \[HBsAg\] and hepatitis B core antibody \[anti-HBc\] and/or hepatitis B surface antibody \[anti-HBs\] testing, when available), hepatitis C, malaria, strongyloidiasis, schistosomiasis, other intestinal parasites, syphilis, gonorrhea, chlamydia, human immunodeficiency virus (HIV), blood lead levels (among children \<17 years old), and mental health. For most conditions, we were unable to collect detailed information on the method of screening used by partners. We assumed the sites conducted screening or testing in accordance with the CDC's *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees* ([Table 1](#pmed.1003065.t001){ref-type="table"}).

10.1371/journal.pmed.1003065.t001

###### Recommended health screenings of refugees and other eligible immigrants during the domestic medical screening examinations conducted in nine selected US sites according to CDC guidelines, 2014--2016[^a^](#t001fn001){ref-type="table-fn"}.

![](pmed.1003065.t001){#pmed.1003065.t001g}

  Health Condition                   Populations Recommended for Screening                                                                                                                                                                                                                                                                                                                                                            Screening
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Tuberculosis**                   All groups                                                                                                                                                                                                                                                                                                                                                                                       IGRA and/or TST
  **Hepatitis B Virus**              All individuals who were born in or most recently lived in countries in which the rate of chronic hepatitis B virus infection is \>2% (intermediate or highly endemic countries) and all individuals from low-endemicity countries if they have hepatitis B virus risk factors or are pregnant                                                                                                   HBsAg and anti-HBc (optional) and/or anti-HBs (optional)
  **Hepatitis C Virus**              High-risk groups, including people who have ever injected illegal drugs, have body art (tattoos, piercings), are human immunodeficiency virus positive, have a history of multiple sex partners or sexually transmitted infections, have a mother positive for hepatitis C virus, received blood products before migration, have a history of chronic hemodialysis, or have other risk factors   Anti-HCV or RIBA or hepatitis C ribonucleic acid PCR
  **Malaria**                        Sub-Saharan African refugees receiving no presumptive treatment before departure or any person from a malaria-endemic country with signs or symptoms of infection                                                                                                                                                                                                                                Laboratory-confirmed via microscopy or rapid diagnostic test
  ***Strongyloides***                Individuals without complete predeparture treatment                                                                                                                                                                                                                                                                                                                                              Laboratory-confirmed microscopy or serology test
  ***Schistosoma***                  Individuals coming from sub-Saharan Africa without complete predeparture treatment (most refugees are treated overseas)                                                                                                                                                                                                                                                                          Laboratory-confirmed microscopy or serology test
  **Intestinal Parasites**           Individuals with no predeparture treatment (most refugees from Middle East, South and Southeast Asia, and Africa are treated overseas)                                                                                                                                                                                                                                                           Laboratory-confirmed stool ova and parasite test
  **Syphilis**                       If no overseas testing documentation: (1) all persons ≥15 years of age, regardless of the overseas results, and (2) refugees \<15 years if they are sexually active/have a history of sexual abuse, have a mother who tests positive, are from a country endemic for other treponemal subspecies                                                                                                 Non-treponemal test (Venereal Disease Research Laboratory or rapid plasma reagin)
  **Gonorrhea**                      Anyone with symptoms or leukocyte esterase positive on urine sample and women and children with history or risk of sexual assault                                                                                                                                                                                                                                                                Laboratory-confirmed testing (not specified)
  **Chlamydia**                      Sexually active women \<25 years old, women \>25 years old with risk factors, women or children with sexual assault history or risk, anyone with symptoms or are leukocyte esterase positive on urine sample                                                                                                                                                                                     Laboratory-confirmed testing (not specified)
  **Human Immunodeficiency Virus**   All groups (opt-out screening)                                                                                                                                                                                                                                                                                                                                                                   Laboratory-confirmed testing (not specified)
  **Blood Lead**                     All children 6 months to 16 years old                                                                                                                                                                                                                                                                                                                                                            Blood lead level from capillary or venous specimen (venous preferred)
  **Mental Health**                  Individuals \>16 years old should be screened for symptoms of major depression and posttraumatic stress disorder                                                                                                                                                                                                                                                                                 RHS-15 or diagnosis or notation of mental condition including posttraumatic stress disorder, depression, anxiety, adjustment disorder, alcohol or substance abuse, and/or generalized anxiety disorder

^a^This table reflects CDC's *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees* in place during the period of this analysis (2014--2016). Changes to the guidelines and broader implementation of overseas intervention programs occurred during and after the data collection for this analysis, which may have affected domestic screening for some groups. Current guidelines can be found at <https://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/domestic-guidelines.html>

Abbreviations: anti-HBc, hepatitis B core antibody; anti-HBs, hepatitis B surface antibody; anti-HCV, hepatitis C antibody; CDC, Centers for Disease Control and Prevention; HBsAg, hepatitis B surface antigen; IGRA, interferon gamma release assay; PCR, polymerase chain reaction; RHS, Refugee Health Screener; RIBA, recombinant immunoblot assay; TST, tuberculin skin test

We used SAS 9.4 (SAS Institute, Cary, NC) to combine, clean, and standardize data from each site, resulting in an initial data set of 107,162 records meeting our inclusion criteria. A unique identifier was available for six sites (*n* = 90,209, 84.2%); data sharing laws in three sites (*n* = 16,953, 15.8%) prevented sharing of unique identifiers. We used the unique identifier to remove 1,621 (1.8%) duplicate records. Most duplicate records (*n* = 1,430, 88.2%) were from one site and related to a reporting error unlikely to have been repeated in other sites, in which the corrected rate of duplicate records was 0.2%. Therefore, we estimate the potential number of duplicate records remaining in the portion of data set without unique identifiers to be low (approximately 0.2%). We presented data individually for the top 10 countries of nationality and last residence by arrival volume and grouped the remaining countries into an "other" category. Denominators for each condition consisted of the total number of persons for whom screening status (e.g., screened or not screened) was available, which resulted in different denominators by condition. For each condition, we excluded data from sites that were only able to provide positive testing results without providing data on how many people were screened for the condition or who did not routinely screen or report data on a specific condition. The denominators used to calculate proportions screened are reported in "Total" column of each table. We calculated frequencies and percentages and their 95% confidence intervals (CIs) for demographic and screening variables and cross-tabulations for the number and proportion of persons screened with valid results for each condition by age, sex, visa type, examination year, countries of nationality, and last residence and for TB only, the screening test type. We used χ^2^ and Fischer exact tests to compare proportions screened by age, sex, visa type, exam year, nationality, and country of last residence. We considered differences in proportions statistically significant at the 0.05 alpha level and examined 95% CIs to assess stratum-specific differences in screening by characteristic. This analysis is reported per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE Checklist](#pmed.1003065.s001){ref-type="supplementary-material"}).

Results {#sec009}
=======

Our analysis data set included 105,541 refugees and other eligible persons who received a domestic medical examination between January 1, 2014, and December 31, 2016, in one of the nine sites. Characteristics of the data set are reported by visa status in [Table 2](#pmed.1003065.t002){ref-type="table"}. All nine sites provided screening data for TB, hepatitis B, HIV, and hepatitis C, resulting in a denominator of 105,541 persons screened for those conditions ([Table 3](#pmed.1003065.t003){ref-type="table"}). Eight sites provided screening data for malaria, schistosomiasis, strongyloidiasis, intestinal parasites, and sexually transmitted infections (STIs), resulting in a denominator of 100,677 persons screened for these infections (Tables [4](#pmed.1003065.t004){ref-type="table"} and [5](#pmed.1003065.t005){ref-type="table"}). All nine sites provided blood lead screening data for children \<17 years old, which is the age recommendation for lead screening in CDC's *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees* (lead screening denominator: 35,118, [Table 6](#pmed.1003065.t006){ref-type="table"}). Finally, five sites provided mental health screening data for 27,712 persons ([Table 6](#pmed.1003065.t006){ref-type="table"}). Four sites did not share mental health screening data because they either did not conduct mental health screening at the time of the domestic screening examination or did not retain mental health screening information in the data sources used for this analysis.

10.1371/journal.pmed.1003065.t002

###### Demographic characteristics of persons receiving a domestic medical examination by visa status in nine US sites, 2014--2016.
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  Characteristics                                                 Visa Status                                                                                                               
  --------------------------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- -------- ------ -------- ------ ----- ------
  **Total (Row %)**                                               105,451       100           4,044         3.8           14,915        14.1          74,025   70.2   11,801   11.2   666   0.6
  **Mean Age, Years (SD)**                                        25.8 (17.1)   28.1 (16.1)   33.2 (13.0)   25.1 (17.8)   19.9 (14.4)   26.2 (16.1)                                         
  **Age (Years)**[^b^](#t002fn003){ref-type="table-fn"}                                                                                                                                     
  **\<5**                                                         12,096        11.5          213           5.3           358           2.4           9,023    12.2   2,447    20.7   55    8.3
  **5--17**                                                       24,614        23.3          930           23.0          989           6.6           19,882   26.9   2,651    22.5   162   24.3
  **18--44**                                                      54,255        51.5          2,267         56.1          10,906        73.1          34,506   46.6   6,215    52.7   361   54.2
  **45--64**                                                      11,714        11.1          552           13.7          2,411         16.2          8,258    11.2   417      3.5    76    11.4
  **65+**                                                         2,762         2.6           82            2.0           251           1.7           2,347    3.2    70       0.6    12    1.8
  **Examination Year**                                                                                                                                                                      
  **2014**                                                        34,548        32.8          1,818         45.0          3,408         22.9          25,410   34.3   3,673    31.1   239   35.9
  **2015**                                                        33,358        31.6          1,240         30.7          6,168         41.4          22,533   30.4   3,190    27.0   227   34.1
  **2016**                                                        37,545        35.6          986           24.4          5,339         35.8          26,082   35.2   4,938    41.8   200   30.0
  **Sex**[^c^](#t002fn004){ref-type="table-fn"}                                                                                                                                             
  **Female**                                                      1,933         47.8          1,933         47.8          5,942         39.8          35,977   48.6   5,291    44.8   374   56.2
  **Male**                                                        2,111         52.2          2,111         52.2          8,970         60.1          38,036   51.4   6,509    55.2   288   43.2
  **Median Days Elapsed between Arrival and Examination (IQR)**   30 (16--53)   57 (40--74)   49 (31--71)   27 (14--47)   27 (14--48)   47 (29--67)                                         
  **Days from Arrival to Exam**                                                                                                                                                             
  **\<30 Days**                                                   53,070        50.3          595           14.7          3,558         23.9          42,284   57.1   6,450    54.7   183   27.5
  **30--90 Days**                                                 48,164        45.7          3,113         77.0          10,173        68.2          29,449   39.8   5,025    42.6   404   60.7
  **\>90 Days**                                                   3,384         3.2           318           7.9           1,009         6.8           1,770    2.4    216      1.8    71    10.7
  **Unknown**                                                     833           0.8           18            0.5           175           1.2           522      0.7    110      0.9    8     1.2
  **Nationality**                                                                                                                                                                           
  **Afghanistan**                                                 11,736        11.1          191           4.7           33            0.2           2,397    3.2    8,977    76.1   138   20.7
  **Bhutan**                                                      4,221         4.0           6             0.2           4             0.0           4,201    5.7    4        0.0    6     0.9
  **Burma**                                                       17,749        16.8          29            0.7           9             0.1           17,674   23.9   29       0.3    8     1.2
  **Democratic Republic of Congo**                                6,554         6.2           28            0.7           ≤3            0.0           6,497    8.8    25       0.2    ≤3    0.5
  **Cuba**                                                        15,459        14.7          29            0.7           14,499        97.2          867      1.2    44       0.4    20    3.0
  **Iran**                                                        7,179         6.8           367           9.1           37            0.3           6,396    8.6    350      3.0    29    4.4
  **Iraq**                                                        16,605        15.8          389           9.6           24            0.2           14,172   19.1   1,963    16.6   57    8.6
  **Somalia**                                                     8,474         8.0           110           2.7           ≤3            0.0           8,288    11.2   44       0.4    30    4.5
  **Syria**                                                       4,258         4.0           82            2.0           ≤3            0.0           4,125    5.6    45       0.4    4     0.6
  **Ukraine**                                                     1,485         1.4           22            0.5           6             0.0           1,362    1.8    93       0.8    ≤3    0.3
  **Other**[^d^](#t002fn005){ref-type="table-fn"}                 11,731        11.1          2,791         69.0          298           2.0           8,046    10.9   227      1.9    369   55.4
  **Last Residence**                                                                                                                                                                        
  **Afghanistan**                                                 8,475         8.0           162           4.0           29            0.2           998      1.4    7,153    60.6   133   20.0
  **Austria**                                                     5,173         4.9           84            2.1           33            0.2           4,773    6.5    270      2.3    13    2.0
  **Cuba**                                                        3,791         3.6           18            0.5           2,997         20.1          741      1.0    24       0.2    11    1.7
  **Iraq**                                                        8,781         8.3           131           3.2           15            0.1           7,089    9.6    1,499    12.7   47    7.1
  **Jordan**                                                      4,851         4.6           44            1.1           5             0.0           4,743    6.4    55       0.5    4     0.6
  **Kenya**                                                       4,361         4.1           19            0.5           ≤3            0.0           4,305    5.8    21       0.2    13    2.0
  **Malaysia**                                                    11,217        10.6          12            0.3           7             0.1           11,167   15.1   26       0.2    5     0.8
  **Nepal**                                                       4,319         4.1           117           2.9           4             0.0           4,188    5.7    4        0.0    6     0.9
  **Thailand**                                                    6,363         6.0           5             0.1           ≤3            0.0           6,338    8.6    16       0.1    ≤3    0.2
  **Turkey**                                                      5,586         5.3           45            1.1           ≤3            0.0           5,369    7.3    162      1.4    7     1.1
  **Other**[^e^](#t002fn006){ref-type="table-fn"}                 42,534        40.3          3,407         84.3          11,816        79.2          24,314   32.9   2,571    21.8   426   64.0

Col% refers to the proportion of persons with characteristics using the total population (in first column) as denominator.

^a^"Other" visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.

^b^Excludes 10 individuals missing age.

^c^Excludes 20 individuals missing sex.

^d^Includes persons with the following nationalities: Missing, Algeria, Andorra, Angola, Armenia, Austria, Azerbaijan, Bangladesh, Belarus, Belize, Benin, Botswana, Brazil, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Republic of Congo, Costa Rica, Côte d'Ivoire, Cyprus, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Estonia, Ethiopia, Fiji, Gabon, Gaza Strip/West Bank, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Haiti, Honduras, India, Indonesia, Ireland, Israel, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Kyrgyzstan, Latvia, Lebanon, Liberia, Libya, Malawi, Malaysia, Maldives, Mali, Mexico, Moldova, Mongolia, Morocco, Mozambique, Namibia, Nepal, the Netherlands, Nicaragua, Niger, Nigeria, North Korea, Norway, Oman, Pakistan, Peru, Philippines, Poland, Polish, Qatar, Romania, Russia, Rwanda, Saudi Arabia, Senegal, Serbia, Sierra Leone, Solomon Islands, South Africa, South Korea, South Sudan, Spain, Sri Lanka, Sudan, Sweden, Taiwan, Tajikistan, Tanzania, Thailand, Togo, Tunisia, Turkey, Turkmenistan, Uganda, United Arab Emirates, Unknown, Uzbekistan, Venezuela, Vietnam, Yemen, Zambia, and Zimbabwe.

^e^Includes persons with the following countries of last residence: Missing, Albania, Algeria, Armenia, Australia, Azerbaijan, Bahrain, Bangladesh, Belarus, Belize, Bhutan, Botswana, Brazil, Burma, Burundi, Cambodia, Cameroon, Canada, Central African Republic, Chad, China, Colombia, Costa Rica, Côte d'Ivoire, Democratic Republic of Congo, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Ethiopia, France, Gabon, Gaza Strip/West Bank, Germany, Ghana, Guatemala, Guinea, Haiti, Honduras, Hong Kong, India, Indonesia, Iran, Israel, Italy, Kazakhstan, Kuwait, Kyrgyzstan, Latvia, Lebanon, Liberia, Libya, Malawi, Mali, Malta, Mauritania, Mexico, Moldova, Mongolia, Morocco, Mozambique, Myanmar, Namibia, the Netherlands, Nicaragua, Nigeria, North Korea, Oman, Pakistan, Panama, Peru, Philippines, Qatar, Republic of Congo, Romania, Russia, Rwanda, Saudi Arabia, Slovakia, Slovenia, Somalia, South Africa, South Korea, Spain, Sri Lanka, Sudan, Sweden, Syria, Tajikistan, Tanzania, Togo, Trinidad and Tobago, Tunisia, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States, Uzbekistan, Venezuela, Vietnam, Yemen, Zambia, Zimbabwe.

Abbreviations: SD, standard deviation

10.1371/journal.pmed.1003065.t003

###### Screening coverage of refugees and other eligible immigrants for tuberculosis infection, hepatitis B, HIV, and hepatitis C by demographic characteristics during domestic medical screening examinations conducted in nine US sites, 2014--2016.
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  Characteristics                                                           Number and Proportion of Persons Screened                                                                                                           
  --------------------------------------------------------------- --------- ------------------------------------------- -------- ------ ------------ --------- ------ ------------ -------- ------ ------------ -------- ------ ------------
  **Total**                                                       105,451   100                                         96,606   91.6   91.4--91.8   101,004   95.8   95.7--95.9   84,687   80.3   80.1--80.6   49,783   47.2   46.9--47.5
  **Age (Years)**[^a^](#t003fn002){ref-type="table-fn"}                                                                                 \<0.001                       \<0.001                      \<0.001                      \<0.001
  **\<5**                                                         12,096    11.5                                        7,489    61.9   61.1--62.8   10,402    86     85.4--86.6   7,862    65.0   64.2--65.9   4,433    36.7   35.8--37.5
  **5--17**                                                       24,614    23.3                                        22,628   91.9   91.6--92.3   23,257    94.5   94.2--94.8   18,275   74.3   73.7--74.8   10,635   43.2   42.6--43.8
  **18--44**                                                      54,255    51.5                                        52,445   96.7   96.5--96.8   53,112    97.9   97.8--98.0   46,105   85     84.7--85.3   26,593   49     48.6--49.4
  **45--64**                                                      11,714    11.1                                        11,351   96.9   96.6--97.2   11,508    98.2   98.0--98.5   10,034   85.7   85.0--86.3   6,330    54     53.1--54.9
  **65+**                                                         2,762     2.6                                         2,683    97.1   96.5--97.8   2,715     98.3   97.8--98.8   2,402    87.0   85.7--88.2   1,789    64.8   63.0--66.6
  **Examination Year**                                                                                                                  \<0.001                       \<0.001                      \<0.001                      \<0.001
  **2014**                                                        34,548    32.8                                        31,788   92     91.7--92.3   33,005    95.5   95.3--95.8   27,148   78.6   78.2--79.0   16,689   48.3   47.8--48.8
  **2015**                                                        33,358    31.6                                        30,585   91.7   91.4--92.0   32,294    96.8   96.6--97.0   28,000   83.9   83.5--84.3   15,980   47.9   47.4--48.4
  **2016**                                                        37,545    35.6                                        34,233   91.2   90.9--91.5   35,705    95.1   94.9--95.3   29,539   78.7   78.3--79.1   17,114   45.6   45.1--46.1
  **Sex**[^b^](#t003fn003){ref-type="table-fn"}                                                                                         \<0.001                       0.0012                       \<0.001                      \<0.001
  **Female**                                                      49,517    47                                          45,211   91.3   91.1--91.6   47,325    95.6   95.4--95.8   39,554   79.9   79.5--80.2   23,767   48     47.6--48.4
  **Male**                                                        55,914    53                                          51,386   91.9   91.7--92.1   53,663    96     95.8--96.1   45,130   80.7   80.4--81.0   26,016   46.5   46.1--46.9
  **Visa**                                                                                                                              \<0.001                       \<0.001                      \<0.001                      \<0.001
  **Refugee**                                                     74,025    70.2                                        67,685   91.4   91.2--91.6   70,656    95.5   95.3--95.6   56,341   76.1   75.8--76.4   35,923   48.5   48.2--48.9
  **Special Immigrant Visa Holder**                               11,801    11.2                                        10,221   86.6   86.0--87.2   11,015    93.3   92.9--93.8   9,806    83.1   82.4--83.8   7,233    61.3   60.4--62.2
  **Asylee**                                                      4,044     3.8                                         3,812    94.3   93.6--95.0   3,967     98.1   97.7--98.5   3,774    93.3   92.6--94.1   2,763    68.3   66.9--69.8
  **Cuban/Haitian Entrant (Parolees)**                            14,915    14.1                                        14,262   95.6   95.3--96.0   14,722    98.7   98.5--98.9   14,161   94.9   94.6--95.3   3,493    23.4   22.7--24.1
  **Other (Nonrefugees)**[^c^](#t003fn004){ref-type="table-fn"}   666       0.6                                         626      94     92.2--95.8   644       96.7   95.3--98.1   605      90.8   88.7--93.0   371      55.7   51.9--59.5
  **Nationality**                                                                                                                       \<0.001                       \<0.001                      \<0.001                      \<0.001
  **Afghanistan**                                                 11,736    11.1                                        10,203   86.9   86.3--87.6   10,982    93.6   93.3--94.0   9,586    81.7   81.0--82.4   7,163    61     60.2--61.9
  **Bhutan**                                                      4,221     4                                           3,839    91.0   90.1--91.8   3,984     94.4   93.7--95.1   2,752    65.2   63.8--66.6   1,851    43.9   42.4--45.4
  **Burma**                                                       17,749    16.8                                        15,839   89.2   88.8--89.7   16,786    94.6   94.2--94.9   13,732   77.4   76.8--78.0   8,604    48.5   47.7--49.2
  **Democratic Republic of Congo**                                6,554     6.2                                         5,909    90.2   89.4--90.9   6,315     96.4   95.9--96.8   4,937    75.3   74.3--76.4   2,799    42.7   41.5--43.9
  **Cuba**                                                        15,459    14.7                                        14,773   95.6   95.2--95.9   15,242    98.6   98.4--98.8   14,623   94.6   94.2--95.0   3,431    22.2   21.5--22.9
  **Iran**                                                        7,179     6.8                                         6,954    96.9   96.5--97.3   7,046     98.2   97.8--98.5   6,787    94.5   94.0--95.1   5,151    71.8   70.7--72.8
  **Iraq**                                                        16,605    15.8                                        15,062   90.7   90.3--91.2   16,057    96.7   96.4--97.0   13,241   79.7   79.1--80.4   8,229    49.6   48.8--50.3
  **Somalia**                                                     8,474     8                                           7,926    93.5   93.0--94.1   8,085     95.4   95.0--95.9   6,502    76.7   75.8--77.6   4,052    47.8   46.8--48.9
  **Syria**                                                       4,258     4                                           3,793    89.1   88.1--90.0   3,985     93.6   92.9--94.3   2,935    68.9   67.5--70.3   1,767    41.5   40.0--43.0
  **Ukraine**                                                     1,485     1.4                                         1,398    94.1   93.0--95.3   1,365     91.9   90.5--93.3   1,153    77.6   75.5--79.8   1,012    68.2   65.8--70.5
  **Other**                                                       11,731    11.1                                        10,910   93.0   92.5--93.5   11,157    95.1   94.7--95.5   8,439    71.9   71.1--72.8   5,724    48.8   47.9--49.7
  **Last Residence**                                                                                                                    \<0.001                       \<0.001                      \<0.001                      \<0.001
  **Afghanistan**                                                 8,475     8                                           7,365    86.9   86.3--87.7   7,905     93.3   92.8--93.8   6,931    81.8   81.0--82.6   5,555    65.6   64.6--66.6
  **Austria**                                                     5,173     4.9                                         5,035    97.4   97.0--97.8   5,069     98.1   97.7--98.4   4,950    95.8   95.2--96.3   3,813    73.8   72.5--74.9
  **Cuba**                                                        3,791     3.6                                         3,603    95.0   94.4--95.8   3,688     97.3   96.8--97.8   3,213    84.8   83.6--85.9   1,494    39.4   37.9--41.0
  **Iraq**                                                        8,781     8.3                                         7,761    88.4   87.8--89.2   8,460     96.4   96.0--96.8   7,446    84.8   84.1--85.6   4,176    47.6   46.5--48.6
  **Jordan**                                                      4,851     4.6                                         4,322    89.1   88.3--90.0   4,585     94.5   93.9--95.2   3,633    74.9   73.7--76.1   2,244    46.3   44.9--47.7
  **Kenya**                                                       4,361     4.1                                         4,043    92.7   92.0--93.5   4,086     93.7   93.0--94.4   3,151    72.3   70.9--73.4   1,954    44.8   43.3--46.3
  **Malaysia**                                                    11,217    10.6                                        9,703    86.5   85.9--87.2   10,651    95     94.6--95.7   8,991    80.2   79.4--80.9   5,002    44.6   43.7--45.5
  **Nepal**                                                       4,319     4.1                                         3,917    90.7   90.2--91.9   4,038     93.5   92.8--94.3   2,843    65.8   64.4--67.3   2,001    46.3   44.8--47.8
  **Thailand**                                                    6,363     6                                           5,941    93.4   93.0--94.2   5,869     92.2   91.6--92.9   4,543    71.4   70.3--72.5   3,561    56     54.7--57.2
  **Turkey**                                                      5,586     5.3                                         5,209    93.3   92.7--94.0   5,416     97     96.5--97.4   4,653    83.3   82.3--84.3   3,348    59.9   58.7--61.2
  **Other**                                                       42,534    40.3                                        39,632   93.2   92.9--93.4   41,227    96.9   96.8--97.1   34,324   80.7   80.3--81.1   16,632   39.1   38.6--39.6
  **Latent Tuberculosis Infection Test Type**                                                                                                                                                                                   
  **Interferon Gamma Release Assay**                              85,972    81.5                                                                                                                                                
  **Tuberculin Skin Test**                                        10,540    10                                                                                                                                                  
  **Not Done**                                                    8,939     8.5                                                                                                                                                 

Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons screened using stratum-specific (row) total as denominator

^a^Excludes 10 individuals missing age.

^b^Excludes 20 individuals missing sex.

^c^"Other" visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus

10.1371/journal.pmed.1003065.t004

###### Screening of refugees and other eligible immigrants for parasitic infections by demographic characteristics during domestic medical screening examinations conducted in eight[^a^](#t004fn002){ref-type="table-fn"} US sites, 2014--2016.

![](pmed.1003065.t004){#pmed.1003065.t004g}

  Characteristics                                                           Number and Proportion of Persons Screened                                                                                                          
  --------------------------------------------------------------- --------- ------------------------------------------- -------- ------ ------------ -------- ------ ------------ -------- ------ ------------ -------- ------ ------------
  **Total**                                                       100,677   100.0                                       16,180   16.1   15.8--16.3   23,964   23.8   23.5--24.1   11,155   11.1   10.9--11.3   56,504   56.1   55.8--56.4
  **Age (Years)**[^b^](#t004fn003){ref-type="table-fn"}                                                                                 \<0.001                      \<0.001                      \<0.001                      \<0.001
  **\<5**                                                         11,417    11.3                                        1,489    13.0   12.4--13.7   3,550    31.1   30.2--31.9   1,397    12.2   11.6--12.8   6,658    58.3   57.4--59.2
  **5**--**17**                                                   23,492    23.3                                        3,591    15.3   14.8--15.7   6,043    25.7   25.2, 26.3   3,137    13.4   12.9--13.8   12,343   52.5   51.9--53.2
  **18**--**44**                                                  51,790    51.4                                        7,910    15.3   15.0--15.6   11,444   22.1   21.7--22.5   5,232    10.1   9.8--10.4    28,808   55.6   55.2--56.1
  **45**--**64**                                                  11,298    11.2                                        2,347    20.8   20.0--21.5   2,332    20.6   19.9--21.4   1,182    10.5   9.9--11.0    6,886    61.0   60.1--61.9
  **65+**                                                         2,670     2.7                                         840      31.5   29.7--33.2   586      22.0   20.4--23.5   207      7.8    6.7--8.8     1,800    67.4   65.6--69.2
  **Examination Year**                                                                                                                  \<0.001                      \<0.001                      \<0.001                      \<0.001
  **2014**                                                        32,742    32.5                                        7,831    23.9   23.5--24.4   7,299    22.3   21.8--22.7   3,679    11.2   10.9--11.6   19,493   59.5   59.0--60.1
  **2015**                                                        31,924    31.7                                        7,057    22.1   21.7--22.6   6,954    21.8   21.3--22.2   3,697    11.6   11.2--11.9   17,410   54.5   54.0--55.1
  **2016**                                                        36,011    35.8                                        1,292    3.6    3.4--3.8     9,711    27.0   26.5--27.4   3,779    10.5   10.2--10.8   19,601   54.4   53.9--55.0
  **Sex**[^c^](#t004fn004){ref-type="table-fn"}                                                                                         \<0.001                      \<0.001                      0.1                          0.3
  **Female**                                                      47,207    46.9                                        7,827    16.6   16.3--16.9   11,576   24.5   24.1--24.9   5,326    11.3   11.0--11.6   26,455   56.0   55.6--56.5
  **Male**                                                        53,450    53.1                                        8,353    15.6   15.3--15.9   12,387   23.2   22.8--23.5   5,828    10.9   10.6--11.2   30,047   56.2   55.8--56.6
  **Visa**                                                                                                                              \<0.001                      \<0.001                      \<0.001                      \<0.001
  **Refugee**                                                     69,923    69.5                                        10,849   15.5   15.2--15.8   15,622   22.3   22.0--22.7   8,441    12.1   11.8--12.3   35,110   50.2   49.8--50.6
  **Special Immigrant Visa Holder**                               11,427    11.4                                        2,834    24.8   24.0--25.6   5,236    45.8   44.9--46.7   249      2.2    1.9--2.5     8,152    71.3   70.5--72.2
  **Asylee**                                                      3,910     3.9                                         2,009    51.4   49.8--53.0   773      19.8   18.5--21.0   184      4.7    4.0--5.4     3,202    81.9   80.7--83.1
  **Cuban/Haitian Entrant (Parolees)**                            14,775    14.7                                        289      2.0    1.7--2.2     2,070    14.0   13.5--14.6   2,172    14.7   14.1--15.3   9,584    64.9   64.1--65.6
  **Other (Nonrefugees)**[^d^](#t004fn005){ref-type="table-fn"}   642       0.6                                         199      31.0   27.4--34.6   263      41.0   37.2--44.8   109      17.0   14.1--19.9   456      71.0   67.5--74.5
  **Nationality**                                                                                                                       \<0.001                      \<0.001                      \<0.001                      \<0.001
  **Afghanistan**                                                 11,400    11.3                                        3,027    26.6   25.7--27.4   5,242    46.0   45.1--46.9   282      2.5    2.2--2.8     8,434    74.0   73.2--74.8
  **Bhutan**                                                      3,781     3.8                                         65       1.7    1.3--2.1     433      11.5   10.4--12.5   481      12.7   11.7--13.8   1,344    35.6   34.0--37.1
  **Burma**                                                       16,402    16.3                                        593      3.6    3.3--3.9     3,226    19.7   19.1--20.3   2,477    15.1   14.6--15.7   6,139    37.4   36.7--38.2
  **Democratic Republic of Congo**                                6,218     6.2                                         551      8.9    8.1--9.5     1,066    17.1   16.2--18.1   1,056    17.0   16.1--17.9   2,005    32.3   31.1--33.4
  **Cuba**                                                        15,300    15.2                                        282      1.8    1.6--2.1     2,350    15.4   14.8--15.9   2,353    15.4   14.8--16.0   9,892    64.7   63.9--65.4
  **Iran**                                                        7,141     7.1                                         3,488    48.8   47.7--50.0   1,703    23.9   22.9--24.8   58       0.8    0.6--1.0     6,360    89.1   88.3--89.8
  **Iraq**                                                        15,970    15.9                                        3,836    24.0   23.4--24.7   2,568    16.1   15.5--16.7   890      5.6    5.2--5.9     8,402    52.6   51.8--53.4
  **Somalia**                                                     7,928     7.9                                         887      11.2   10.5--11.9   3,034    38.3   37.2--39.3   2,199    27.7   26.8--28.7   3,481    43.9   42.8--45.0
  **Syria**                                                       4,171     4.1                                         216      5.2    4.5--5.9     1,014    24.3   23.0--25.6   209      5.0    4.4--5.7     2,208    52.9   51.4--54.5
  **Ukraine**                                                     1,403     1.4                                         335      23.9   21.7--26.1   936      66.7   64.3--69.2   74       5.3    4.1--6.4     1,038    74.0   71.7--76.3
  **Other**                                                       10,963    10.9                                        2,900    26.5   25.6--27.3   2,392    21.8   21.1--22.6   1,076    9.8    9.3--10.4    7,201    65.7   64.8--66.6
  **Last Residence**                                                                                                                    \<0.001                      \<0.001                      \<0.001                      \<0.001
  **Afghanistan**                                                 8,170     8.1                                         2,504    30.6   29.6--31.6   4,367    53.5   52.4--54.5   212      2.6    2.3--2.9     6,397    78.3   77.4--79.2
  **Austria**                                                     5,173     5.1                                         2,715    52.5   51.1--53.8   1,127    21.8   20.7--22.9   36       0.7    0.5--0.9     4,792    92.6   91.9--93.4
  **Cuba**                                                        3,642     3.6                                         126      3.5    2.9--4.1     1,831    50.3   48.7--51.9   1,849    50.8   49.1--52.4   2,668    73.3   71.8--74.7
  **Iraq**                                                        8,333     8.3                                         1,715    20.6   19.7--21.5   1,335    16.0   15.2--16.8   461      5.5    5.0--6.0     3,716    44.6   43.5--45.7
  **Jordan**                                                      4,727     4.7                                         663      14.0   13.0--15.0   1,082    22.9   21.7--24.1   291      6.2    5.5--6.8     2,708    57.3   55.9--58.7
  **Kenya**                                                       3,989     4.0                                         411      10.3   9.4--11.3    1,090    27.3   25.9--28.7   877      22.0   20.7--23.3   1,506    37.8   36.3--39.3
  **Malaysia**                                                    10,283    10.2                                        458      4.5    4.1--4.9     1,528    14.9   14.2--15.6   332      3.2    2.9--3.6     3,476    33.8   32.9--34.7
  **Nepal**                                                       3,859     3.8                                         141      3.7    3.1--4.3     479      12.4   11.4--13.5   494      12.8   11.8--13.9   1,290    33.4   31.9--34.9
  **Thailand**                                                    5,946     5.9                                         277      4.7    4.1--5.2     1,639    27.6   26.4--28.7   2,118    35.6   34.4--36.8   2,282    38.4   37.1--39.6
  **Turkey**                                                      5,444     5.4                                         1,645    30.2   29.0--31.4   1,457    26.8   25.6--27.9   331      6.1    5.5--6.7     3,817    70.1   68.9--71.3
  **Other**                                                       41,111    40.8                                        5,525    13.4   13.1--13.8   8,029    19.5   19.2--19.9   4,154    10.1   9.8--10.4    23,852   58.0   57.5--58.5

Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons screened using stratum-specific (row) total as denominator.

^a^Excludes data from one site that did not collect information on total numbers of persons screened for these conditions.

^b^Excludes 10 individuals missing age.

^c^Excludes 20 individuals missing sex.

^d^"Other" visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.

Abbreviation: CI, confidence interval

10.1371/journal.pmed.1003065.t005

###### Screening for sexually transmitted infections of refugees and other eligible immigrants by demographic characteristics during domestic medical screening examinations conducted in eight[^a^](#t005fn002){ref-type="table-fn"} US sites, 2014--2016.

![](pmed.1003065.t005){#pmed.1003065.t005g}

  Characteristics                                                 Number and Proportion of Persons Screened                                                                                    
  --------------------------------------------------------------- ------------------------------------------- ------- -------- ------ ------------ -------- ------ ------------ ------- ------ ------------
  **Total**                                                       100,677                                     100     60,713   60.3   60.0--60.6   14,102   14     13.8--14.2   4,687   4.7    4.5--4.8
  **Age (Years)**[^b^](#t005fn003){ref-type="table-fn"}                                                                               \<0.001                      \<0.001                     \<0.001
  **\<5**                                                         11,417                                      11.3    1,045    9.2    8.6--9.7     75       0.7    0.5--0.8     10      0.1    0.03--0.1
  **5**--**17**                                                   23,492                                      23.3    6,705    28.5   28.0--29.1   2,206    9.4    9.0--9.8     753     3.2    3.0--3.4
  **18**--**44**                                                  51,790                                      51.4    41,512   80.2   79.8--80.5   10,214   19.7   19.4--20.1   3,226   6.2    6.0--6.4
  **45**--**64**                                                  11,298                                      11.2    9,230    81.7   81.0--82.4   1,340    11.9   11.3--12.5   573     5.1    4.7--5.5
  **65+**                                                         2,670                                       2.7     2,212    82.9   81.4--84.3   259      9.7    8.6--10.8    125     4.7    3.9--5.5
  **Exam Year**                                                                                                                       \<0.001                      \<0.001                     \<0.001
  **2014**                                                        32,742                                      32.5    19,714   60.2   59.7--60.7   3,047    9.3    9.0--9.6     1,159   3.5    3.3--3.7
  **2015**                                                        31,924                                      31.7    20,015   62.7   62.2--63.2   4,952    15.5   15.1--15.9   1,490   4.7    4.4--4.9
  **2016**                                                        36,011                                      35.8    20,984   58.3   57.8--58.8   6,103    17     16.6--17.3   2,038   5.7    5.4--5.9
  **Sex**[^c^](#t005fn004){ref-type="table-fn"}                                                                                       \<0.001                      \<0.001                     \<0.001
  **Female**                                                      47,207                                      46.9    27,999   59.3   58.9--59.8   8,913    18.9   18.5--19.2   2,459   5.2    5.0--5.4
  **Male**                                                        53,450                                      53.1    32,712   61.2   60.8--61.6   5,189    9.7    9.5--10.0    2,228   4.2    4.0--4.3
  **Visa**                                                                                                                            \<0.001                      \<0.001                     \<0.001
  **Refugee**                                                     69,923                                      69.5    37,224   53.2   52.9--53.6   10,174   14     14.3--14.8   4,401   6.3    6.1--6.5
  **Special Immigrant Visa Holder**                               11,427                                      11.4    6,634    58.1   57.2--59.0   1,886    16.5   15.8--17.2   25      0.2    0.1--0.3
  **Asylee**                                                      3,910                                       3.9     3,134    80.2   78.9--81.4   791      20.2   19.0--21.5   10      0.3    0.1--0.4
  **Cuban/Haitian Entrant (Parolees)**                            14,775                                      14.7    13,283   89.9   89.4--90.4   1,111    7.52   7.1--7.9     192     1.3    1.1--1.5
  **Other (Nonrefugees)**[^d^](#t005fn005){ref-type="table-fn"}   642                                         0.6     438      68.2   64.6--71.8   140      21.8   18.6--25.0   59      9.2    7.0--11.4
  **Nationality**                                                                                                                     \<0.001                      \<0.001                     \<0.001
  **Afghanistan**                                                 11,400                                      11.32   6,545    57.4   56.5--58.3   2,172    19.1   18.3--19.8   62      0.5    0.4--0.7
  **Bhutan**                                                      3,781                                       3.76    1,980    52.4   50.8--54.0   624      16.5   15.3--17.7   293     7.8    6.9--8.6
  **Burma**                                                       16,402                                      16.3    6,903    42.1   41.3--42.8   2,049    12.5   12.0--13.0   1,371   8.4    7.9--8.8
  **Democratic Republic of Congo**                                6,218                                       6.2     3,032    48.8   47.5--50.0   919      14.8   13.9--15.7   369     5.9    5.4--6.5
  **Cuba**                                                        15,300                                      15.2    13,642   89.2   88.7--89.7   1,155    7.6    7.1--8.0     231     1.5    1.3--1.7
  **Iran**                                                        7,141                                       7.1     6,197    86.8   85.7--87.6   1,019    14.3   13.5--15.1   42      0.6    0.4--0.8
  **Iraq**                                                        15,970                                      15.9    9,883    61.9   61.1--62.6   1,659    10.4   9.9--10.9    373     2.3    2.1--2.6
  **Somalia**                                                     7,928                                       7.9     3,730    47.1   46.0--48.2   1,686    21.3   20.4--22.2   1,304   16.5   15.6--17.3
  **Syria**                                                       4,171                                       4.1     1,737    41.6   40.2--43.1   451      10.8   9.9--11.8    102     2.5    2.0--2.9
  **Ukraine**                                                     1,403                                       1.4     838      59.7   57.2--62.3   453      32.3   29.8--34.7   69      4.9    3.8--6.1
  **Other**                                                       10,963                                      10.9    6,226    56.8   55.9--57.7   1,915    17.5   16.8--19.2   471     4.3    3.9--4.7
  **Last Residence**                                                                                                                  \<0.001                      \<0.001                     \<0.001
  **Afghanistan**                                                 8,170                                       8.1     4,550    55.7   54.6--56.8   1,648    20.2   19.3--21.0   40      0.5    0.3--0.6
  **Austria**                                                     5,173                                       5.1     4,635    89.6   88.8--90.4   621      12     11.1--12.9   31      0.6    0.4--0.8
  **Cuba**                                                        3,642                                       3.6     2,842    78     76.7--79.4   451      12.4   11.3--13.5   197     5.4    4.7--6.1
  **Iraq**                                                        8,333                                       8.3     5,342    64.1   63.1--65.1   835      10     9.4--10.7    218     2.6    2.3--3.0
  **Jordan**                                                      4,727                                       4.7     2,350    49.7   48.3--51.1   578      12.2   11.3--13.2   144     3.1    2.6--3.5
  **Kenya**                                                       3,989                                       4       1,868    46.8   45.3--48.4   801      20.1   18.8--21.3   545     13.7   12.6--14.7
  **Malaysia**                                                    10,283                                      10.2    4,429    43.1   42.1--44.0   841      8.2    7.7--8.7     436     4.2    3.4--4.6
  **Nepal**                                                       3,859                                       3.8     1,987    51.5   49.9--53.1   727      18.8   17.6--20.1   318     8.2    7.4--9.1
  **Thailand**                                                    5,946                                       5.9     2,464    41.4   40.2--42.7   1,241    20.9   19.8--21.9   899     15.1   14.2--16.0
  **Turkey**                                                      5,444                                       5.4     3,651    67.1   65.8--68.3   910      16.7   15.7--17.7   133     2.4    2.0--2.9
  **Other**                                                       41,111                                      40.8    26,595   64.7   64.2--65.2   5,449    13.3   12.9--13.6   1,726   4.2    4.0--4.4

Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons screened using stratum-specific (row) total as denominator.

^a^Excludes data from one site that did not collect information on total numbers of persons screened for these conditions.

^b^Excludes 10 individuals missing age.

^c^Excludes 20 individuals missing sex.

^d^"Other" visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.

Abbreviation: CI, confidence interval

10.1371/journal.pmed.1003065.t006

###### Screening for blood lead levels and mental health of refugees and other eligible immigrants by demographic characteristics during domestic medical screening examinations conducted in multiple sites, 2014--2016.

![](pmed.1003065.t006){#pmed.1003065.t006g}

  Characteristics                                                 Number and Proportion of Persons Screened                                                                       
  --------------------------------------------------------------- ------------------------------------------- ------ -------- ------ ------------ -------- ------ -------- ------ ------------
  **Total**                                                       35,118                                      100    31,108   88.6   88.3--88.9   27,712   100    10,208   36.8   36.3--37.4
  **Age (Years)**[^c^](#t006fn004){ref-type="table-fn"}                                                                              \<0.001                                      \<0.001
  **≤2**                                                          6,875                                       19.6   5,635    82.0   81.1--82.9   1,970    7.1    18       0.9    0.5--1.3
  **3--6**                                                        9,741                                       27.7   8,867    91.0   90.5--91.6   2,754    9.9    28       1.0    0.6--1.4
  **7--12**                                                       11,836                                      33.7   10,809   91.3   90.8--91.8   3,457    12.5   37       1.1    0.7--1.4
  **13--16**                                                      6,656                                       19.0   5,796    87.1   86.3--87.9   2,015    7.3    455      22.6   20.8--24.4
  **17--44**                                                                                                                                      14,386   51.9   7,861    54.6   53.8--55.5
  **45--64**                                                                                                                                      2,680    9.7    1,580    59     57.1--60.8
  **65+**                                                                                                                                         449      1.6    228      50.8   46.2--55.4
  **Exam Year**                                                                                                                      \<0.001                                      \<0.001
  **2014**                                                        10,761                                      30.6   9,409    87.4   86.8--88.1   8,940    32.3   2,943    32.9   32.0--33.9
  **2015**                                                        10,722                                      30.5   9,479    88.4   87.8--89.0   8,226    29.7   3,122    38     36.9--39.0
  **2016**                                                        13,635                                      38.8   12,220   89.6   89.1--90.1   10,546   38.1   4,143    39.3   38.4--40.2
  **Sex**[^d^](#t006fn005){ref-type="table-fn"}                                                                                      0.03                                         0.02
  **Female**                                                      17,007                                      48.4   15,004   88.2   87.7--88.7   13,232   47.7   4,781    36.1   35.3--37.0
  **Male**                                                        18,103                                      51.5   16,102   89     88.5--89.4   14,466   52.2   5,426    37.5   36.7--38.3
  **Visa Type**                                                                                                                      \<0.001                                      \<0.001
  **Refugee**                                                     27,566                                      78.5   24,757   89.8   89.5--90.2   23,351   84.3   7,427    31.8   31.2--32.4
  **Special Immigrant Visa Holder**                               4,998                                       14.2   4,270    85.4   84.5--86.4   1,128    4.1    347      30.8   28.1--33.5
  **Asylee**                                                      1,083                                       3.1    845      78     75.6--80.5   197      0.7    125      63.5   56.7--70.2
  **Cuban/Haitian Entrant (Parolees)**                            1,269                                       3.6    1,067    84.1   82.1--86.1   2,956    10.7   2,257    76.4   74.8--77.9
  **Other (Nonrefugees)**[^e^](#t006fn006){ref-type="table-fn"}   202                                         0.6    169      83.7   78.6--88.8   80       0.3    52       65.0   54.6--75.5
  **Nationality**                                                                                                                    \<0.001                                      \<0.001
  **Afghanistan**                                                 4,986                                       14.2   4,175    83.7   82.7--84.8   1,249    4.5    360      28.8   26.3--31.3
  **Bhutan**                                                      1,194                                       3.4    1,098    92     90.4--93.5   2,266    8.2    790      34.9   32.9--36.8
  **Burma**                                                       6,675                                       19     5,982    89.6   88.9--90.4   7,654    27.6   2,349    30.7   29.7--31.7
  **Democratic Republic of Congo**                                3,223                                       9.2    3,025    93.9   93.0--94.7   3,132    11.3   994      31.7   30.1--33.4
  **Cuba**                                                        1,395                                       4.0    1,196    85.7   83.9--87.6   3,287    11.9   2,481    75.5   74.0--77.0
  **Iran**                                                        934                                         2.7    697      74.6   71.8--77.4   100      0.4    51       51.0   41.2--60.8
  **Iraq**                                                        5,515                                       15.7   4,852    88     87.1--88.8   2,708    9.8    1,089    40.2   38.4--42.1
  **Somalia**                                                     3,795                                       10.8   3,501    92.3   91.4--93.1   3,026    10.9   844      27.9   26.3--29.5
  **Syria**                                                       2,252                                       6.4    2,033    90.3   89.1--91.5   1,201    4.3    374      31.1   28.5--33.8
  **Ukraine**                                                     536                                         1.5    442      82.5   79.2--85.7   297      1.1    75       25.3   20.3--30.2
  **Other**                                                       4,613                                       13.1   4,107    89     88.1--89.9   2,792    10.1   801      28.7   27.0--30.4
  **Last Residence**                                                                                                                 \<0.001                                      \<0.001
  **Afghanistan**                                                 3,809                                       10.8   3,163    83     81.9--84.2   891      3.2    265      29.7   26.7--32.7
  **Austria**                                                     577                                         1.6    398      69     65.2--75.8   9        0      1        11.1   0--48.3\*
  **Cuba**                                                        505                                         1.4    452      89.5   86.8--92.2   2,598    9.4    1,948    75     73.3--76.7
  **Iraq**                                                        3,084                                       8.8    2,729    88.5   87.4--89.6   1,575    5.7    673      42.7   40.3--45.2
  **Jordan**                                                      2,236                                       6.4    2,006    98.7   88.5--91.0   1,238    4.5    408      33.0   30.3--35.6
  **Kenya**                                                       1,960                                       5.6    1,802    91.9   90.7--93.1   1,846    6.7    482      26.1   24.1--28.1
  **Malaysia**                                                    4,027                                       11.5   3,561    88.4   87.4--89.4   5,337    19.3   1,833    34.4   33.1--35.6
  **Nepal**                                                       1,295                                       3.7    1,187    91.7   90.2--93.2   2,441    8.8    811      33.2   31.4--35.1
  **Thailand**                                                    2,768                                       7.9    2,768    93     92.0--93.9   2,362    8.5    482      20.4   18.8--22.0
  **Turkey**                                                      1,764                                       5.0    1,764    88.2   86.6--89.7   899      3.2    326      36.3   33.1--39.4
  **Other**                                                       13,093                                      37.3   11,681   89.2   88.7--89.8   8,516    30.7   2,979    35.0   34.0--36.0

Col% refers to proportion of persons with characteristics using the total population (in first column) as denominator, and Row% refers to proportion of persons screened using stratum-specific (row) total as denominator.

^a^Total for lead screening only, excludes persons ≥17 years old.

^b^Total for mental health screening only, excludes persons from four sites not reporting information on mental health screening.

^c^Excludes 10 individuals missing age.

^d^Excludes two records with unknown sex for lead, one with unknown sex for mental health.

^e^"Other" visa category includes victims of trafficking, unaccompanied minors, and persons with an unspecified visa status.

Abbreviation: CI, confidence interval

Approximately 51% of persons in our initial data set were between 18 and 44 years old, and 34.8% were under age 18 ([Table 2](#pmed.1003065.t002){ref-type="table"}). Fifty-three percent were male. Burma (16.8%), Iraq (15.8%), Cuba (14.7%), Afghanistan (11.1%), and Somalia (8.0%) contributed the largest volumes of arrivals by nationality ([Table 2](#pmed.1003065.t002){ref-type="table"}). The data set mostly comprised refugees (70.2%), Cuban/Haitian parolees (14.1%), SIVHs (11.2%), and asylees (3.8%) ([Table 2](#pmed.1003065.t002){ref-type="table"}). Fifty percent of examinations took place within 30 days of US arrival ([Table 2](#pmed.1003065.t002){ref-type="table"}). Timing of screening after arrival varied by visa type (refugees and SIVH: median 27 days; parolees: 49 days; asylees: 57 days, [Table 2](#pmed.1003065.t002){ref-type="table"}), consistent with anticipated flows through the resettlement process.

Most individuals (96,606 of 105,541; 91.6%, 95% CI 91.4--91.8) were screened for TB ([Table 3](#pmed.1003065.t003){ref-type="table"}); of those, 89.0% were screened with an IGRA test. Screening differed significantly by age, with 95.5% (95% CI 95.3--95.6, collapsed from [Table 3](#pmed.1003065.t003){ref-type="table"}) of those aged 6 years or older screened for TB compared with 61.9% (95% CI 61.1--62.8) of children aged 5 and younger (χ^2^ *p* \< 0.001). Screening was lowest among SIVH (86.6%, 95% CI 86.0--87.2) compared with all visa types (91.6%, 95% CI 91.4--91.8). Afghans had the lowest proportion of persons screened for TB (86.9%, 95% CI 86.3--87.6); Iranians had the highest (96.9%, 95% CI 96.5--97.3).

In our data set, hepatitis B virus (HBV) screening was reported for 101,004 of 105,541 persons (95.8%, 95% CI 95.7--95.9) ([Table 3](#pmed.1003065.t003){ref-type="table"}). Screening coverage among children \<5 years old was lowest (86.0%, 95% CI 85.4--86.6); ≥98.3% of persons ≥45 years old were screened. A lower proportion of SIVHs were screened (93.3%, 95% CI 92.9--93.8) compared with parolees and asylees (≥98.1%). Screening coverage was lowest among Ukrainians (91.9%, 95% CI, 90.5--93.3) and highest among Cubans (98.6%, 95% CI 98.4--98.8).

HIV screening was reported for 84,687 of 105,541 persons (80.3%, 95% CI 80.1--80.6) ([Table 3](#pmed.1003065.t003){ref-type="table"}). Screening coverage differed significantly across age groups (χ^2^ *p* \< 0.001), with the lowest coverage among children less than 5 years old (65.0%, 95% CI 64.2--65.9). The percentage of adults ≥18 years old screened for HIV was 85.2% (95% CI 84. 9--85.4, data collapsed from [Table 3](#pmed.1003065.t003){ref-type="table"}). Among top arrival nationalities, screening ranged from 65.2% (95% CI 63.8--66.6) among Bhutanese to 94.6% (95% CI 94.2--95.0) among Cubans.

Hepatitis C virus (HCV) screening was reported for 49,783 (47.2%, 95% CI 46.9--47.5) of 105,541 persons ([Table 3](#pmed.1003065.t003){ref-type="table"}). Screening coverage increased with age; 56.1% (95% CI 55.3--56.9, data collapsed from [Table 3](#pmed.1003065.t003){ref-type="table"}) of adults 45 years and older at the time of their examination (ages corresponding loosely to persons born between 1945 and 1965, a population with greater HCV infection risk in the US) were tested for HCV; screening coverage among person \<45 years old was 45.8% (95% CI 45.5--46.1, data collapsed from [Table 3](#pmed.1003065.t003){ref-type="table"}). Asylees had the highest screening coverage (68.3%, 95% CI 66.9--69.8). The screening coverage of persons from countries with high or high-moderate HCV burden \[[@pmed.1003065.ref015]\] included 68.2% (95% CI 65.8--70.5) of Ukrainians, 42.7% (95% CI 41.5--43.9) of Congolese (Democratic Republic), and 41.5% (95% CI 40.0--43.0) of Syrians.

Our data set consisted of 100,677 persons with data on screening coverage for malaria, *Strongyloides*, *Schistosoma*, and other intestinal parasites. In this data set, 16,180 (16.1%, 95% CI 15.8--16.3) persons were reported screened for malaria ([Table 4](#pmed.1003065.t004){ref-type="table"}). Asylees had the highest screening coverage (51.4%, 95% CI 49.8--53.0). Screening declined from 23.9% (95% CI 23.5--24.4) of persons receiving a domestic medical examination in 2014 to 3.6% (95% CI 3.4--3.8) of persons arriving in 2016. Nationalities with the highest proportion of persons screened included Iranians (48.8%, 95% CI 47.7--50.0) and Afghans (26.6%, 95% CI 25.7--27.4). People with a last residence in Austria, Afghanistan, or Turkey had the highest screening percentage.

Of the 100,677 persons screened for intestinal parasites, 23,964 (23.8%, 95% CI 23.5--24.1) were screened for *Strongyloides* infection ([Table 4](#pmed.1003065.t004){ref-type="table"}). Ukrainians (66.7%, 95% CI 64.3--69.2), Afghans (46.0%, 95% CI 45.1--46.9), and Somalis (38.3%, 95% CI 37.2--39.3) had the highest proportion of persons screened for *Strongyloides*. Screening was highest among persons last residing in Afghanistan (53.5%, 95% CI 52.4--54.5) or Cuba (50.3%, 95% CI 48.7--51.9). *Schistosoma* infection screening was reported for 11,155 of 100,677 (11.1%, 95% CI 10.9--11.3) persons; screening was highest among persons 5--17 years old (13.4%, 95% CI 12.9--13.8). Parolees (14.7%, 95% CI 14.1--15.3) and refugees (12.1%, 95% CI 11.8--12.3), Somalis (27.7%, 95% CI 26.8--28.7), and persons last residing in Cuba (50.8%, 95% CI 49.1--52.4) had the highest proportions of persons screened.

Approximately 56% (95% CI 55.8--56.4) of 100,677 persons were screened for other intestinal parasites, such as *Ascaris* ([Table 4](#pmed.1003065.t004){ref-type="table"}). Screening coverage was highest among asylees (81.9%, 95% CI 80.7--83.1), SIVHs (71.3%, 95% CI 70.5--72.2) and parolees (64.9%, 95% CI 64.1--65.6), Iranians (89.1%, 95% CI 88.3--89.8), and Afghans (74.0%, 95% CI 73.2, 74.8). Screening was highest among persons with a last residence in Austria (92.6%, 95% CI 91.9--93.4), Afghanistan (78.3%, 95% CI 77.4--79.2), and Cuba (73.3%, 95% CI 71.8--74.7).

Among 100,677 persons with screening data for STIs, 60,713 (60.3%, 95% CI 60.0--60.6) were screened for syphilis ([Table 5](#pmed.1003065.t005){ref-type="table"}). Proportions of persons screening differed significantly by age (χ^2^ *p* \< 0.001). Screening coverage was lowest among children younger than 5 years (9.2%, 95% CI 8.6--9.7) and 5--17 years (28.5%, 95% CI 28.0--29.1) compared with persons 18 years and older (80.5%, 95% CI 80.2--80.8, data collapsed from [Table 5](#pmed.1003065.t005){ref-type="table"}). Screening was highest among parolees (89.9%, 95% CI 89.4--90.4) and asylees (80.2%, 95% CI 78.9--81.4).

A smaller proportion of our data set were screened for chlamydia (14,102 of 100,677 persons, 14.0%, 95% CI 13.8--14.2). Chlamydia screening was highest among persons aged 18--44 years, SIVHs and asylees, women, and Ukrainians. Gonorrhea screening results were available for 4,687 of 100,677 persons (4.7%, 95% CI 4.5--4.8). Screening was highest among persons 18--44 years, refugees, and Somalis.

The majority (31,108 of 35,118; 88.6%, 95% CI 88.3--88.9) of children \<17 years of age had blood lead screening results ([Table 6](#pmed.1003065.t006){ref-type="table"}). Screening coverage was significantly lower among children ≤2 years old (82.0%, 95% CI 81.1--82.9) compared with children ≥3 years old (90.2%, 95% CI 89.9--90.6, data collapsed from [Table 6](#pmed.1003065.t006){ref-type="table"}). Screening was highest among refugees (89.8%, 95% CI 89.5--90.2) and lowest among asylees (78.0%, 95% CI 75.6--80.5) and was lower among children with a last residence in Austria (69.0%, 95% CI 65.2--75.8) compared with other countries of last residence.

Among the five sites that provided mental health screening data (denominator: 27,712 persons), screening was reported for 10,208 (36.8%, 95% CI 36.3--37.4) persons ([Table 6](#pmed.1003065.t006){ref-type="table"}). Mental health screening was low among children \<16 years old (3.9% 95% CI 3.5--4.3, data collapsed from [Table 6](#pmed.1003065.t006){ref-type="table"}); 16 is the age at which mental health screening is recommended in CDC's *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees*. Screening among persons ≥16 years old was 54.6% (95% CI 53.9--55.3, data collapsed from [Table 6](#pmed.1003065.t006){ref-type="table"}). The proportion of persons who received mental health screening increased slightly between 2014 and 2016, and screening proportion differed by examination year (χ^2^ *p* \< 0.001). A higher proportion of asylees (63.5%, 95% CI 56.7--70.2) and parolees (76.4%, 95% CI 74.8--77.9) received mental health screening than refugees (31.8, 95% CI 31.2--32.4) and SIVHs (30.8%, 95% CI 28.1--33.5).

Discussion {#sec010}
==========

This analysis used a multistate data set to describe disease screenings conducted during the domestic medical examination for refugees and other eligible populations. These results provide new evidence that most persons eligible for refugee health benefits are screened for several health conditions after US arrival through the domestic medical examination, particularly for TB (91.6%), HBV (95.8%), HIV (80.3%), and blood lead (88.6% of persons \<17 years old). Screening coverage for other health conditions, including STIs, parasites, and mental health, was lower. For most conditions, screening coverage increased with age and differed by nationality and country of last residence. Differences in proportions screened by sex and year of health assessment, although statistically significant, were not of clinical or public health significance for most conditions.

To our knowledge, this is the first analysis of a large, multisite data set to assess screening coverage resulting from the domestic medical examination recommended for newly arrived refugees and other eligible visa holders in the US. Our data are consistent with prior studies that have reported high screening coverage for TB (93%) \[[@pmed.1003065.ref016]\] and HBV (92.5%) during the domestic medical examination \[[@pmed.1003065.ref011],[@pmed.1003065.ref013],[@pmed.1003065.ref016]\]. Compared with two studies reporting screening coverage for intestinal parasites among refugees in Minnesota (64%--80%) \[[@pmed.1003065.ref016],[@pmed.1003065.ref017]\], our analysis found a lower screening coverage among refugees (50.2%). However, the Minnesota studies predate the current overseas presumptive parasite treatment program for US-bound refugees. Now, screening for intestinal parasites may be considered based on clinical symptoms and results of diagnostic testing (e.g., eosinophilia). Reports on screening coverage during the domestic medical examination for other conditions were lacking for comparison.

Our findings indicate that most persons undergoing the domestic medical examination receive several routine health screenings recommended in the US, resulting in higher screening coverage in this population compared with the broader US population for several conditions. In the US, TB and HBV screening are recommended for populations at highest risk of infections \[[@pmed.1003065.ref018],[@pmed.1003065.ref019]\], including foreign-born persons from countries with moderate to high burden of the diseases \[[@pmed.1003065.ref020],[@pmed.1003065.ref021]\]. In our analysis, 91.6% of persons who received a domestic medical examination were screened for TB compared with roughly 63% of all foreign-born respondents in the 2011--2012 National Health and Nutritional Examination Survey (self-reported data representative of persons residing in the US) \[[@pmed.1003065.ref022]\]. Almost 96% of persons in our data set were screened for HBV compared with 19% of patients enrolled in four US healthcare organizations regardless of risk factors (*N* = 1,248,558) \[[@pmed.1003065.ref023]\]. CDC recommends screening all adults for HIV at least once in their lifetime \[[@pmed.1003065.ref024]\]. We found that 85% of adults were tested for HIV during the domestic screening examination, which is higher than the testing rate among the US adult population (\<40% in 2016--2017) \[[@pmed.1003065.ref024]\]. Finally, during the period of this analysis, one-time HCV screening was recommended for all US adults born between 1945 and 1965, regardless of risk factors \[[@pmed.1003065.ref025],[@pmed.1003065.ref026]\]. The HCV screening rate among persons in our data set falling into this birth cohort (\>44 years old at the time of their examination) was 56.1% (95% CI 55.3--56.9, data collapsed from [Table 3](#pmed.1003065.t003){ref-type="table"}), which is higher than the HCV screening rate among the general US population born between 1945 through 1965 (13% ever screened in 2015) \[[@pmed.1003065.ref027]\]. The relatively high screening rates for TB, HBV, HIV, and HCV during the domestic examination demonstrates that the domestic examination is an effective opportunity to identify eligible new arrivals with these conditions and link them to care in the US. However, efforts to explore why screening opportunities for these conditions are missed during the domestic medical examination may further improve screening coverage.

Screening coverage for malaria and intestinal parasites varied widely by visa type, nationality, and country of last residence. Screening coverage for malaria and intestinal parasites was lower among refugees than among other visa holders, which is likely the result of the overseas presumptive parasite treatment; if complete overseas treatment is documented, domestic screening is not required \[[@pmed.1003065.ref028]\]. Ukrainians are likely overscreened for *Strongyloides* infection based on unclear guidance for screening for refugees originating from Europe, where *Strongyloides* is not hyperendemic \[[@pmed.1003065.ref029]\]. Domestic screening is still recommended for persons who are symptomatic or have signs of infection such as eosinophilia, those who were ineligible for overseas treatment because of contraindications, and those from countries where presumptive treatment is not available.

The CDC *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees* recommend screening for certain STIs based on whether overseas screening was done (for syphilis), age, and other risk factors, including history of sexual assault \[[@pmed.1003065.ref007]\]. The proportions of refugees and SIVH screened for syphilis (53% and 58%, respectively) were lower compared with other visa types, likely reflecting the impact of overseas immigration screening requirements for syphilis. Domestic clinicians are recommended to review overseas syphilis testing results and to repeat testing in the US if overseas results are unavailable. For most of the period of this analysis, gonorrhea testing was not required overseas (overseas testing began October 1, 2016), and chlamydia testing has never been required overseas. For these infections, the domestic guidelines recommend screening for patients with certain risk factors (age, sexual history, or symptoms). Domestic gonorrhea and chlamydia screening among these populations could reflect presence of risk factors or symptoms, availability of overseas testing results, clinic screening policies for these conditions, or cultural barriers that discourage refugees from disclosing risk factors \[[@pmed.1003065.ref030]\].

Blood lead screening was reported for 88.6% of all children \<17 years old; children ≤2 years old had the lowest screening rates (82.0%). CDC's *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees* recommend screening children aged 6 months through 16 years for lead upon arrival, but our data did not permit us to uniformly identify children younger than 1 year. Consequently, 82.0% is likely an underestimate of the proportion of children appropriately screened in this youngest age group. However, children aged 1--2 still had lower screening coverage compared with older children. Prior investigations have found a high prevalence of elevated blood lead levels among refugees \[[@pmed.1003065.ref012],[@pmed.1003065.ref031]--[@pmed.1003065.ref033]\], and infants and young children are at greatest risk of both lead exposures and the resulting negative health outcomes \[[@pmed.1003065.ref033]\]. Understanding and addressing barriers to lead screening among infants and young children is critical to ensuring appropriate care. Moreover, results from blood lead screening performed during the domestic medical exam serve as a baseline for the recommended repeat screening 3--6 months following resettlement that may highlight potential domestic exposures.

CDC's *Guidelines for the U*.*S*. *Domestic Medical Examination for Newly Arriving Refugees* encourage screening for depression and posttraumatic stress disorders (PTSDs) among people over age 16. In our analysis, mental health screening coverage among adults was between 50% and 55% and was lowest among refugees (31.8%) and SIVHs (30.8%). The relatively low rate of mental health screening could be the result of multiple factors. First, immigration-related screening has historically prioritized infectious disease screening in order to reduce disease risks to refugees and their resettlement communities. Second, mental health screening may be deferred from the domestic medical examination, which is typically administered within the first 90 days of US arrival, because refugees may be in a period of adjustment in which mental health symptoms are not as apparent \[[@pmed.1003065.ref034],[@pmed.1003065.ref035]\], or they may not feel comfortable disclosing symptoms during the initial examination \[[@pmed.1003065.ref007]\]. After building a rapport with clinicians, both care providers and resettled refugees may be better positioned to screen for and address mental health issues. Finally, research has found that screening is often informally administered, which may have made it difficult to capture in our data source, and screening may be less likely to be administered if culturally and linguistically competent mental health services are unavailable in the screening jurisdiction for referrals \[[@pmed.1003065.ref036],[@pmed.1003065.ref037]\]. However, we were not able to ascertain why mental health screening was not done in this analysis. Meta-analyses of mental health among refugees and other conflict-affected populations have estimated prevalence of depression (\>23%) and PTSDs (also \>23%) \[[@pmed.1003065.ref038],[@pmed.1003065.ref039]\] that exceed the estimated prevalence of these conditions among other populations in the US, such as veterans (PTSD 8%) and the US household population (depression 7.6%). The high prevalence of mental health conditions coupled with the low screening coverage in our analysis highlights the need for increased investigation of when and how mental health screening is being conducted among refugees and other populations receiving the domestic medical examination, barriers to mental health screening and services, and effective treatments for these populations.

This analysis was subject to limitations. The data upon which we relied were often collected primarily for programmatic rather than surveillance purposes, which yielded gaps in information (e.g., screening test type). Sites used screening tests and algorithms that may differ in sensitivity and specificity to detect conditions, and they collected and shared data differently. Therefore, our findings only reflect those sites contributing data and not all refugee and other persons receiving the domestic medical screening examination in the US. Some sites did not routinely collect information on each health condition included in the analysis, but this may not mean that they did not screen for these conditions; conversely, it also is possible that sites reported testing done outside the domestic medical examination, depending on their source of data and method of data extraction. One site captured only positive screening outcomes for parasitic infections and STIs without a denominator of all persons tested; we excluded these results from our calculations. Screening for some conditions is based on patient age, region of origin, or other characteristics (e.g., blood lead, malaria, STIs), so not all patients should have received screening for each health condition. Screening is done at the discretion of the examining clinician, with some healthcare providers being more likely to screen for certain conditions than others; and all screening tests can be declined by the recipients, which may be influenced by sex, age, cultural factors, and type of testing. We were not able to capture information on why an individual may not have been screened. Finally, we were unable to collect data on linkage to care in this population and could not evaluate how well the domestic medical screening examination connected people to the US healthcare system for further care.

This analysis found that refugees and other recipients of the domestic screening examination are well screened for several health conditions shortly after arrival in the US. This indicates that the domestic medical examination is effective at its intended purpose to screen newly resettled persons for health conditions, protecting both their health and the health of the receiving community. Future directions for research could include exploration of screening practices during the domestic medical examination, particularly mental health screening, and assessment of the domestic examination's effectiveness at connecting recipients to the US healthcare system.

Our assessment of a large, multisite data set found that screening coverage for several key health conditions---TB, hepatitis B and C, and HIV---was high during domestic screening examination, particularly when compared with screening rates among the US population. The domestic medical examination provides a good opportunity to improve the health of newly arrived refugees, SIVHs, asylees, and parolees by ensuring they receive several routine recommended health screenings.
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